Zacks Research Issues Negative Estimate for FMS Earnings

Fresenius Medical Care AG (NYSE:FMS) – Investment analysts at Zacks Research reduced their Q4 2024 earnings per share estimates for shares of Fresenius Medical Care in a report released on Monday, December 30th. Zacks Research analyst I. Bandyopadhyay now expects that the company will post earnings per share of $0.38 for the quarter, down from their prior estimate of $0.39. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.55 per share. Zacks Research also issued estimates for Fresenius Medical Care’s Q1 2025 earnings at $0.39 EPS, Q2 2025 earnings at $0.42 EPS, Q3 2025 earnings at $0.53 EPS, Q4 2025 earnings at $0.54 EPS, FY2025 earnings at $1.87 EPS, Q1 2026 earnings at $0.46 EPS, Q2 2026 earnings at $0.47 EPS, Q3 2026 earnings at $0.59 EPS and FY2026 earnings at $2.13 EPS.

A number of other brokerages also recently weighed in on FMS. Truist Financial increased their price objective on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Bank of America raised Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a report on Monday, December 2nd. Berenberg Bank started coverage on Fresenius Medical Care in a report on Wednesday, November 6th. They issued a “buy” rating and a $25.60 target price on the stock. Finally, StockNews.com started coverage on shares of Fresenius Medical Care in a research report on Thursday, November 28th. They set a “strong-buy” rating for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Fresenius Medical Care presently has a consensus rating of “Hold” and a consensus target price of $24.30.

Fresenius Medical Care Price Performance

FMS opened at $22.15 on Wednesday. The company’s 50-day simple moving average is $22.21 and its two-hundred day simple moving average is $20.64. Fresenius Medical Care has a 52-week low of $17.93 and a 52-week high of $24.31. The stock has a market capitalization of $13.00 billion, a P/E ratio of 18.31, a P/E/G ratio of 0.96 and a beta of 0.93. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37.

Institutional Trading of Fresenius Medical Care

Several hedge funds have recently bought and sold shares of the stock. Creative Planning lifted its stake in shares of Fresenius Medical Care by 18.9% during the 2nd quarter. Creative Planning now owns 40,140 shares of the company’s stock valued at $766,000 after buying an additional 6,373 shares in the last quarter. Verition Fund Management LLC bought a new stake in Fresenius Medical Care during the third quarter valued at about $237,000. Wulff Hansen & CO. lifted its position in shares of Fresenius Medical Care by 1,809.0% in the second quarter. Wulff Hansen & CO. now owns 343,429 shares of the company’s stock valued at $6,556,000 after acquiring an additional 325,439 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Fresenius Medical Care by 11.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 22,161 shares of the company’s stock worth $472,000 after acquiring an additional 2,233 shares during the period. Finally, Quantinno Capital Management LP grew its position in shares of Fresenius Medical Care by 78.9% during the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after purchasing an additional 48,554 shares in the last quarter. Institutional investors own 8.37% of the company’s stock.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.